Cargando…
Hepatocellular carcinoma in Gaucher disease: an international case series
Gaucher disease (GD) is associated with an increased risk for malignancies. Next to hematological malignancies, the development of solid tumors in several organs has been described. The liver is one of the major storage sites involved in GD pathogenesis, and is also affected by liver-specific compli...
Autores principales: | Regenboog, Martine, van Dussen, Laura, Verheij, Joanne, Weinreb, Neal J., Santosa, David, vom Dahl, Stephan, Häussinger, Dieter, Müller, Meike N., Canbay, Ali, Rigoldi, Miriam, Piperno, Alberto, Dinur, Tama, Zimran, Ari, Mistry, Pramod K., Salah, Karima Yousfi, Belmatoug, Nadia, Kuter, David J., Hollak, Carla E. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133179/ https://www.ncbi.nlm.nih.gov/pubmed/29423829 http://dx.doi.org/10.1007/s10545-018-0142-y |
Ejemplares similares
-
Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018) -
Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022) -
Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019) -
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
por: Dinur, Tama, et al.
Publicado: (2020) -
High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2023)